Abstract
Dementia is a syndrome resulting from chronic or progressive brain disease. Around 40% of worldwide dementia can be prevented or delayed by modifying 12 risk factors: low educational attainment in early life, mid-life hypertension, mid-life obesity, hearing loss, traumatic brain injury, excessive alcohol consumption, smoking, depression, physical inactivity, social isolation, diabetes mellitus, and air pollution. There is growing evidence that gastrointestinal tract microbiota may significantly contribute to dementia pathogenesis. In particular, gut dysbiosis can trigger metabolic diseases and the progression of low-grade systemic inflammation, being involved in much of the major modifiable risk factors. In this review, we focus on studies that have evaluated the association between modifiable risk factors for dementia and the role of gut microbiota. We also suggest clinical implications for researchers in dementia-gut microbiota related fields.
Keywords: Dementia, risk factor, gut microbiota, dysbiosis, lifestyle, prevention.
Current Alzheimer Research
Title:Modifiable Risk Factors for Dementia: The Role of Gut Microbiota
Volume: 18 Issue: 13
Author(s): Cristian Cabrera, Paloma Vicens and Margarita Torrente*
Affiliation:
- Department of Psychology, CRAMC (Research Center for Behavior Assessment), Tarragona,Spain
- Laboratory of Toxicology and Environmental Health, TECNATOX, Institut d’Investigació Sanitària Pere Virgili, Reus, Spain
Keywords: Dementia, risk factor, gut microbiota, dysbiosis, lifestyle, prevention.
Abstract: Dementia is a syndrome resulting from chronic or progressive brain disease. Around 40% of worldwide dementia can be prevented or delayed by modifying 12 risk factors: low educational attainment in early life, mid-life hypertension, mid-life obesity, hearing loss, traumatic brain injury, excessive alcohol consumption, smoking, depression, physical inactivity, social isolation, diabetes mellitus, and air pollution. There is growing evidence that gastrointestinal tract microbiota may significantly contribute to dementia pathogenesis. In particular, gut dysbiosis can trigger metabolic diseases and the progression of low-grade systemic inflammation, being involved in much of the major modifiable risk factors. In this review, we focus on studies that have evaluated the association between modifiable risk factors for dementia and the role of gut microbiota. We also suggest clinical implications for researchers in dementia-gut microbiota related fields.
Export Options
About this article
Cite this article as:
Cabrera Cristian , Vicens Paloma and Torrente Margarita*, Modifiable Risk Factors for Dementia: The Role of Gut Microbiota, Current Alzheimer Research 2021; 18 (13) . https://dx.doi.org/10.2174/1567205018666211215152411
DOI https://dx.doi.org/10.2174/1567205018666211215152411 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Elucidation of the Folding Intermediates and Aggregate Formation of Hemoglobin Induced by Acetonitrile: A Multispectroscopic Approach
Protein & Peptide Letters The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung Injury
Current Pharmaceutical Design Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Insulin Resistance and Polycystic Ovary Syndrome
Current Pharmaceutical Design Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology Metal-dithiocarbamate complexes: chemistry and biological activity
Mini-Reviews in Medicinal Chemistry Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Uric Acid and Oxidative Stress
Current Pharmaceutical Design Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development
Current Pharmaceutical Design Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Role of Ca2+-Sensitive K+ Currents in Controlling Ventricular Repolarization: Possible Implications for Future Antiarrhytmic Drug Therapy
Current Medicinal Chemistry